Latest Car T News

Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.

Carma delivered record Q1 FY2027 revenue of $44.3 million and gross profit of $3.5 million after retail vehicle sales more than doubled year on year. The stronger trading result came with lower total gross profit per unit and $10.2 million of operating cash outflow.

CAR Group's Brazilian subsidiary webmotors has agreed to buy a 51% stake in Auto Avaliar for R$543 million, or approximately A$144 million. The acquisition would expand webmotors into digital B2B vehicle valuation and trading, although completion still depends on Brazilian regulatory approvals.

INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.

PARKD’s FY26 annual report puts the company’s funding position under sharper scrutiny after a steep revenue decline, a $1.26 million loss and $367,714 in cash. Its east-coast expansion produced new facilities, partnerships and demonstrations, but the next test is converting that platform into contracted work quickly enough.

Barramundi’s portfolio returned 3.0% on a gross basis in the September quarter, ahead of the ASX 200’s 1.3% gain. CSL, Ansell, MAAS Group and PWR Holdings led the recovery, although the NZX-listed investment company still traded at a 17.2% discount to NAV.

Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.

AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.

European Metals has given in-principle approval to replace Cinovec’s two gas-fired rotary kilns with a single kiln that can run on gas or electricity. Testwork indicates comparable or improved lithium recovery at lower temperatures, with expected reductions in processing-plant capital and operating costs.

Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.

Harmoney has reaffirmed its A$16 million-plus FY27 Cash NPAT target after growing its loan book 9% to A$912 million. The new Australian intermediary channel generated A$7 million in loans within two months, while credit quality and margins remained stable.

MA Financial delivered strong third-quarter growth across lending, asset management and advisory, while warning that residential property credit conditions have forced a temporary redemption suspension. The group still expects underlying FY26 EPS to be materially higher than FY25.